Related Experiment Video
Updated: Oct 2, 2026
Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
Published on: December 27, 2017
Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by
Russell L Basser1, Elizabeth O'Flaherty, Michael Green
1Centre for Developmental Cancer Therapeutics, Department of Haematology and Medical Oncology, Ludwig Institute for Cancer Research, Royal Melbourne Hospital, 45 Poplar Road, Parkville, Victoria 3052, Australia. russell_basser@csl.com.au
Abstract:
Clinical trials of thrombopoietin (TPO), the central regulator of megakaryocytopoiesis, have revealed few side effects associated with its use. We here report a case of pancytopenia associated with the development of neutralizing antibodies to TPO that occurred in a patient who had undergone multicycle chemotherapy with multiple cycles of subcutaneous administration of pegylated recombinant human megakaryocyte growth and development factor. Samples of the patient's bone marrow showed trilineage hypoplasia with absence of myeloid, erythroid, and megakaryocyte progenitor cells but with elevated endogenous levels of erythropoietin, granulocyte colony-stimulating factor, and stem-cell factor. To our knowledge, this is the first report of an aplastic anemia-like syndrome associated with neutralizing antibodies to TPO.
